Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial

Citation
Anker SD, Butler J, Filippatos GS, et al. Eur J Heart Fail 2019;21:1279–87.